ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

ScinoPharm, DSM Win Manufacturing Deals

by Jean-François Tremblay
February 14, 2011 | APPEARED IN VOLUME 89, ISSUE 7

Taiwan’s ScinoPharm has won a contract to produce vilazodone, the active ingredient in Clinical Data’s drug Viibryd. Used to treat major depressive disorder in adults, Viibryd was recently approved by FDA. ScinoPharm says it will be Clinical Data’s sole active ingredient supplier using a manufacturing process ScinoPharm developed. Separately, DSM has signed an agreement with NKT Therapeutics to develop and manufacture the biotech firm’s lead product, a monoclonal antibody called iNKT. NKT develops natural killer T cells that can be used to treat asthma, cancer, infectious diseases, autoimmune diseases, and dermatitis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment